股票 
板块 
用户 
资讯 癌症免疫治疗领域的年度盛会——肿瘤免疫治疗学会（Society for Immunotherapy of Cancer，SITC）年会 SITC 2026，将于2026年11月4日至8日在美国亚利桑那州凤凰城的凤凰城会议中心（Phoenix Convention Center）举行。作为全球规模最大的癌症免疫治疗学术会议之一，本届年会将汇聚全球顶尖的肿瘤免疫学家、临床医生与生物医药研发人员，分享最新科学发现，共话肿瘤免疫治疗的前沿方向与突破。
01
海报研究成果亮点抢先看
2026
本届SITC年会上，药康生物将带来五项前沿研究成果的壁报展示，聚焦T细胞衔接器（TCE）诱导的细胞因子释放综合征（CRS）评价、PD-1/VEGF双特异性抗体、体内CAR-T疗法、双特异性T细胞衔接器疗效与毒性评价，以及mRNA肿瘤疫苗等肿瘤免疫治疗前沿热点，系统展示从人源化小鼠模型、免疫细胞移植到体内药效评价的一体化临床前研究平台。
Friday, November 6, 2026
Poster Hall Hours: 10 a.m.–2 p.m., 5–7 p.m. MT
Abstract 659
用于临床前评价T细胞衔接剂诱导的细胞因子释放综合征（CRS）的人源化NCG小鼠模型表征
Characterization of humanized NCG mouse models for preclinical evaluation of T cell engager-induced cytokine release syndrome
Abstract 661
双靶点人源化PD-1/PD-L1与VEGF小鼠模型的开发，用于肿瘤免疫治疗中PD-1/VEGF双特异性抗体的评价
Development of dual humanized PD-1/PD-L1 and VEGF mouse model for evaluating PD-1/VEGF bispecific antibodies in cancer immunotherapy
Saturday, November 7, 2026
Poster Hall Hours: 10 a.m.–2 p.m., 6–8:10 p.m. MT
Abstract 208
用于快速评价体内（in vivo）CAR-T疗法的体外-体内一体化平台开发
Development of an integrated in vitro and in vivo platform for rapid evaluation of in vivo CAR-T therapies
Abstract 660
双特异性T细胞衔接器在人源化小鼠模型中的疗效与毒性评价
Evaluation of efficacy and toxicity of bispecific T-cell engagers in humanized mouse models
Abstract 862
利用HLA人源化小鼠模型全面评价mRNA肿瘤疫苗的一体化临床前平台
An integrated preclinical platform utilizing HLA-humanized mouse models for comprehensive evaluation of mRNA cancer vaccines
?? 海报地点
PCC-North Building-Lower Level-Exhibition Halls 4-5-6；以上时间均为美国凤凰城当地时间。
02
诚邀交流，共话前沿
2026
我们诚挚邀请各位与会专家、同仁莅临724号展位，与我们的科学团队面对面交流。无论您正专注于T细胞或NK细胞疗法、双特异性抗体与T细胞衔接器、免疫检查点通路、肿瘤疫苗，还是其他免疫调节方向，我们都期待与您探讨研究计划，并分享如何通过精准的人源化模型与专业的临床前评价方案，助力您的下一代免疫疗法研发。
03
药康生物提供一站式临床前解决方案
2026
从人源化小鼠模型、免疫细胞移植到体内药效研究，药康生物为新兴免疫疗法的开发提供全系列临床前模型与研究方案。我们的平台覆盖T细胞与NK细胞疗法、双特异性抗体与T细胞衔接器、免疫检查点通路、肿瘤疫苗及其他免疫调节疗法，帮助研究者在更具临床相关性的临床前环境中评估治疗活性。
我们持续深耕客户需求，不断探索与创新。针对双特异性抗体、T细胞衔接器（TCE）、细胞疗法（如体内CAR-T评价）、肿瘤疫苗等前沿创新治疗模式，我们正着力构建和完善其在临床前肿瘤免疫模型中的疗效与安全性评价体系，以应对日益复杂的研发挑战。
03
预约一对一洽谈，让交流更高效
2026
为更高效地与您沟通，我们特别开放一对一科学家会谈预约。您可发送邮件至 sales@gempharmatech.com，提前锁定与我们的专家深入交流的时间，获取量身定制的临床前研究方案建议，让这次SITC之行收获满满。
从疾病机制探索到免疫治疗的疗效与安全性评价，药康生物凭借全面的模型资源与专业的技术服务，助力您的肿瘤免疫药物研发快速推进。期待在凤凰城与您相见，携手推进新一代癌症免疫治疗！
The annual flagship event in cancer immunotherapy—the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), SITC 2026—will be held from November 4 to 8, 2026,at the Phoenix Convention Center in Phoenix, Arizona, USA. As one of the largest and most influential conferences dedicated to cancer immunotherapy, this annual meeting will bring together leading cancer immunologists, clinicians, and biopharmaceutical researchers from around the world to share the latest scientific discoveries and discuss cutting-edge advances and breakthroughs in cancer immunotherapy.
01
A Sneak Peek at Our Poster Highlights
2026
At SITC 2026, GemPharmatech will present five posters featuring cutting-edge research, focusing on T-cell engager (TCE)-induced cytokine release syndrome (CRS) evaluation, PD-1/VEGF bispecific antibodies, in vivo CAR-T therapies, efficacy and toxicity evaluation of bispecific T-cell engagers, and mRNA cancer vaccines. These posters will systematically demonstrate our integrated preclinical platform spanning humanized mouse models, immune cell engraftment, and in vivo efficacy evaluation.
Friday, November 6, 2026
Abstract 659: Characterization of humanized NCG mouse models for preclinical evaluation of T cell engager-induced cytokine release syndrome
Abstract 661: Development of dual humanized PD-1/PD-L1 and VEGF mouse model for evaluating PD-1/VEGF bispecific antibodies in cancer immunotherapy
Saturday, November 7, 2026
Abstract 208: Development of an integrated in vitro and in vivo platform for rapid evaluation of in vivo CAR-T therapies
Abstract 660: Evaluation of efficacy and toxicity of bispecific T-cell engagers in humanized mouse models
Abstract 862:An integrated preclinical platform utilizing HLA-humanized mouse models for comprehensive evaluation of mRNA cancer vaccines
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6; all times are in Mountain Time (Phoenix local time).
02
Join Us for In-Depth Discussions
2026
We sincerely invite all attending experts and colleagues to visit us at Booth #724 for face-to-face discussions with our scientific team. Whether your focus is T-cell or NK-cell therapies, bispecific antibodies and T-cell engagers, immune checkpoint pathways, cancer vaccines, or other immune-modulating approaches, we look forward to exploring your research plans and sharing how our precise humanized models and professional preclinical evaluation solutions can accelerate your next-generation immunotherapy R&D.
03
One-Stop Preclinical Solutions
in Immuno-Oncology
2026
From humanized mouse models and immune cell engraftment to in vivo efficacy studies, GemPharmatech provides a full range of preclinical models and research solutions to support the development of emerging immunotherapies. Our platforms cover T-cell and NK-cell therapies, bispecific antibodies and T-cell engagers, immune checkpoint pathways, cancer vaccines, and other immune-modulating approaches, helping researchers evaluate therapeutic activity in more clinically relevant preclinical settings.
We continuously deepen our understanding of client needs and pursue exploration and innovation. For novel therapeutic modalities such as bispecific antibodies, T-cell engagers (TCEs), cell therapies (e.g., in vivo CAR-T evaluation), and cancer vaccines, we are actively building and refining efficacy and safety evaluation systems within preclinical immuno-oncology models to address increasingly complex R&D challenges.
04
Schedule a One-on-One Meeting
2026
To ensure efficient communication, we are pleased to offer scheduled one-on-one meetings with our scientists. You can email us at sales@gempharmatech.com to reserve a time slot in advance for an in-depth discussion with our experts and receive tailored recommendations on preclinical research strategies to make the most of your SITC experience.
From disease mechanism exploration to efficacy and safety evaluation of immunotherapies, GemPharmatech leverages comprehensive model resources and professional technical services to accelerate your cancer immunotherapy R&D. We look forward to meeting you in Phoenix and advancing the next generation of cancer immunotherapy together.
作者｜Zoe
审核｜小麦
编辑｜Kloe
就到这了，文末点个??给小编加个鸡腿吧~
扫码立刻享受1v1咨询！
关于药康生物
江苏集萃药康生物科技股份有限公司（科创板代码：688046）是一家专注于实验动物小鼠模型研发、生产及非临床研究服务的国家级高新技术企业，同时是科技部认定的国家遗传工程小鼠资源库共建单位。 依托CRISPR/Cas9、ES打靶等在内的基因编辑技术，公司建立了国际一流的基因修饰动物模型研发平台，拥有近3万种自主知识产权的基因工程小鼠模型品系，其中包括基因敲除/条件性敲除小鼠品系（"斑点鼠计划"）、药靶基因人源化模型、复杂疾病模型、系列免疫缺陷小鼠品系、无菌小鼠品系以及用于抗体药物发现的NeoMab?全人源抗体转基因小鼠，为全球科研机构、CRO公司及医药企业提供全面的模型资源支持。公司提供从基因编辑定制（包括转基因TG、基因敲除KO、基因敲入KI及点突变PM等）、模型繁育到功能药效分析的全流程一站式服务，服务范围涵盖肿瘤、自身免疫性疾病、代谢心血管疾病、神经退行性疾病、感染性疾病及罕见病等重点疾病领域，具体包括靶点验证、药效学评价和非GLP安全性评价等临床前研究。 药康生物致力于成为全球实验动物模型领域的领导者，通过持续深化基因编辑技术的创新应用和资源整合，为生命科学研究和生物医药产业提供高质量的动物模型和技术服务，推动人类健康事业发展。
点赞
收藏
分享
评论 (0)